-Reuters
Barclays Maintains Overweight on Avantor, Raises Price Target to $26
Barclays analyst Luke Sergott maintains Avantor (NYSE:AVTR) with a Overweight and raises the price target from $23 to $26.
Related Posts
Blue Water Vaccines Announces An Exclusive, Global License Agreement For Chlamydia Vaccine Candidate Development From The University Of Texas Health San Antonio
Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or "the Company") a biopharmaceutical company developing transformational vaccines to address significant global health challenges,
Fear & Greed Index Remains In ‘Extreme Greed’ Zone After Dow Snaps 3-Session Losing Streak
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday.
U.S. stocks closed higher on Monday after all three major indices fell last week, with the Dow Jones losing around 2%, recording its worst weekly performance since March.
Global Payments Dips Over 11% After Q1 Earnings – Read Why
Global Payments Inc. shares plummet over 9% post-Q1 earnings, despite surpassing EPS estimates and revenue expectations, amid cautious FY24 outlook.